oxford biomedica plc
oxford biomedica plc Company Information
Company Number
03252665
Website
www.oxfordbiomedica.co.ukRegistered Address
windrush court transport way, oxford, OX4 6LT
Industry
Research and experimental development on biotechnology
Telephone
01865783000
Next Accounts Due
June 2024
Group Structure
View All
Shareholders
-0%
oxford biomedica plc Estimated Valuation
Pomanda estimates the enterprise value of OXFORD BIOMEDICA PLC at £331.5m based on a Turnover of £140m and 2.37x industry multiple (adjusted for size and gross margin).
oxford biomedica plc Estimated Valuation
Pomanda estimates the enterprise value of OXFORD BIOMEDICA PLC at £0 based on an EBITDA of £-3.9m and a 10.01x industry multiple (adjusted for size and gross margin).
oxford biomedica plc Estimated Valuation
Pomanda estimates the enterprise value of OXFORD BIOMEDICA PLC at £440.2m based on Net Assets of £204.7m and 2.15x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Oxford Biomedica Plc Overview
Oxford Biomedica Plc is a live company located in oxford, OX4 6LT with a Companies House number of 03252665. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in September 1996, it's largest shareholder is unknown. Oxford Biomedica Plc is a mature, mega sized company, Pomanda has estimated its turnover at £140m with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Oxford Biomedica Plc Health Check
Pomanda's financial health check has awarded Oxford Biomedica Plc a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 3 areas for improvement. Company Health Check FAQs
4 Strong
5 Regular
3 Weak
Size
annual sales of £140m, make it larger than the average company (£3.5m)
£140m - Oxford Biomedica Plc
£3.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 30%, show it is growing at a faster rate (14.1%)
30% - Oxford Biomedica Plc
14.1% - Industry AVG
Production
with a gross margin of 49.4%, this company has a comparable cost of product (53%)
49.4% - Oxford Biomedica Plc
53% - Industry AVG
Profitability
an operating margin of -21.6% make it less profitable than the average company (-0.4%)
-21.6% - Oxford Biomedica Plc
-0.4% - Industry AVG
Employees
with 929 employees, this is above the industry average (44)
929 - Oxford Biomedica Plc
44 - Industry AVG
Pay Structure
on an average salary of £92.8k, the company has an equivalent pay structure (£77.9k)
£92.8k - Oxford Biomedica Plc
£77.9k - Industry AVG
Efficiency
resulting in sales per employee of £150.7k, this is equally as efficient (£136.2k)
£150.7k - Oxford Biomedica Plc
£136.2k - Industry AVG
Debtor Days
it gets paid by customers after 117 days, this is later than average (51 days)
117 days - Oxford Biomedica Plc
51 days - Industry AVG
Creditor Days
its suppliers are paid after 70 days, this is close to average (70 days)
70 days - Oxford Biomedica Plc
70 days - Industry AVG
Stock Days
it holds stock equivalent to 65 days, this is more than average (48 days)
65 days - Oxford Biomedica Plc
48 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 123 weeks, this is more cash available to meet short term requirements (35 weeks)
123 weeks - Oxford Biomedica Plc
35 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 48.7%, this is a similar level of debt than the average (50%)
48.7% - Oxford Biomedica Plc
50% - Industry AVG
OXFORD BIOMEDICA PLC financials
Oxford Biomedica Plc's latest turnover from December 2022 is £140 million and the company has net assets of £204.7 million. According to their latest financial statements, Oxford Biomedica Plc has 929 employees and maintains cash reserves of £141.3 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 139,989,000 | 142,797,000 | 87,728,000 | 64,060,000 | 66,778,000 | 37,590,000 | 27,776,000 | 15,909,000 | 13,618,000 | 5,375,000 | 7,756,000 | 7,718,000 | 11,153,000 | 19,120,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 70,808,000 | 60,157,000 | 41,655,000 | 35,723,000 | 33,261,000 | 18,442,000 | 11,835,000 | 5,839,000 | 4,416,000 | 1,140,000 | 667,000 | 555,000 | -593,000 | 437,000 |
| Gross Profit | 69,181,000 | 82,640,000 | 46,073,000 | 28,337,000 | 33,517,000 | 19,148,000 | 15,941,000 | 10,070,000 | 9,202,000 | 4,235,000 | 7,089,000 | 7,163,000 | 11,746,000 | 18,683,000 |
| Admin Expenses | 99,401,000 | 61,872,000 | 51,767,000 | 42,804,000 | 19,602,000 | 24,816,000 | 27,254,000 | 24,153,000 | 19,815,000 | 17,058,000 | 17,576,000 | 21,601,000 | 23,757,000 | 24,413,000 |
| Operating Profit | -30,220,000 | 20,768,000 | -5,694,000 | -14,467,000 | 13,915,000 | -5,668,000 | -11,313,000 | -14,083,000 | -10,613,000 | -12,823,000 | -10,487,000 | -14,438,000 | -12,011,000 | -5,730,000 |
| Interest Payable | 16,729,000 | 888,000 | 912,000 | 6,526,000 | 8,972,000 | 3,299,000 | 4,924,000 | 1,891,000 | 235,000 | 4,000 | 3,000 | 8,000 | 15,000 | 33,000 |
| Interest Receivable | 973,000 | 0 | 34,000 | 104,000 | 71,000 | 38,000 | 34,000 | 26,000 | 53,000 | 64,000 | 141,000 | 144,000 | 222,000 | 669,000 |
| Pre-Tax Profit | -45,976,000 | 19,880,000 | -6,572,000 | -20,889,000 | 5,014,000 | -11,761,000 | -20,307,000 | -16,982,000 | -10,798,000 | -12,763,000 | -10,349,000 | -14,302,000 | -11,804,000 | -5,094,000 |
| Tax | 817,000 | -869,000 | 327,000 | 4,823,000 | 2,527,000 | 2,744,000 | 3,666,000 | 3,963,000 | 2,137,000 | 1,667,000 | 1,619,000 | 1,671,000 | 1,514,000 | 1,579,000 |
| Profit After Tax | -45,159,000 | 19,011,000 | -6,245,000 | -16,066,000 | 7,541,000 | -9,017,000 | -16,641,000 | -13,019,000 | -8,661,000 | -11,096,000 | -8,730,000 | -12,631,000 | -10,290,000 | -3,515,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -39,157,000 | 19,011,000 | -6,245,000 | -16,066,000 | 7,541,000 | -9,017,000 | -16,641,000 | -13,019,000 | -8,661,000 | -11,096,000 | -8,730,000 | -12,631,000 | -10,294,000 | -3,515,000 |
| Employee Costs | 86,238,000 | 54,658,000 | 45,669,000 | 33,627,000 | 25,265,000 | 18,094,000 | 16,197,000 | 11,455,000 | 8,038,000 | 6,449,000 | 6,087,000 | 5,762,000 | 5,789,000 | 9,187,000 |
| Number Of Employees | 929 | 759 | 609 | 500 | 377 | 295 | 247 | 196 | 113 | 95 | 83 | 86 | 73 | 69 |
| EBITDA* | -3,861,000 | 33,224,000 | 3,926,000 | -8,680,000 | 18,272,000 | -322,000 | -11,313,000 | -12,456,000 | -9,514,000 | -11,756,000 | -9,516,000 | -10,516,000 | -10,967,000 | -5,419,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 138,790,000 | 73,333,000 | 75,909,000 | 65,896,000 | 46,757,000 | 28,324,000 | 28,171,000 | 24,396,000 | 8,944,000 | 4,070,000 | 3,902,000 | 4,213,000 | 730,000 | 631,000 |
| Intangible Assets | 105,886,000 | 52,000 | 73,000 | 95,000 | 117,000 | 97,000 | 1,330,000 | 1,743,000 | 2,106,000 | 2,633,000 | 2,931,000 | 3,106,000 | 6,683,000 | 11,119,000 |
| Investments & Other | 0 | 0 | 0 | 0 | 10,966,000 | 2,954,000 | 657,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 5,010,000 | 3,605,000 | 3,605,000 | 3,964,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 150,000 | 0 |
| Total Fixed Assets | 244,676,000 | 73,385,000 | 75,982,000 | 65,991,000 | 46,874,000 | 28,421,000 | 29,501,000 | 26,139,000 | 11,050,000 | 6,703,000 | 6,833,000 | 7,319,000 | 7,413,000 | 11,750,000 |
| Stock & work in progress | 12,625,000 | 9,521,000 | 6,912,000 | 2,579,000 | 4,251,000 | 3,332,000 | 2,202,000 | 2,706,000 | 1,407,000 | 680,000 | 0 | 0 | 0 | 0 |
| Trade Debtors | 45,006,000 | 35,945,000 | 47,327,000 | 26,172,000 | 26,585,000 | 5,705,000 | 1,969,000 | 8,529,000 | 3,961,000 | 1,677,000 | 315,000 | 187,000 | 1,760,000 | 88,000 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 16,565,000 | 8,802,000 | 6,599,000 | 3,873,000 | 0 | 11,383,000 | 4,935,000 | 2,401,000 | 1,192,000 | 915,000 | 1,390,000 | 2,613,000 | 2,885,000 | 4,540,000 |
| Cash | 141,285,000 | 108,944,000 | 46,743,000 | 16,243,000 | 32,244,000 | 14,329,000 | 15,335,000 | 9,355,000 | 14,195,000 | 2,169,000 | 8,956,000 | 6,835,000 | 6,653,000 | 6,802,000 |
| misc current assets | 23,000 | 74,000 | 239,000 | 2,719,000 | 2,446,000 | 2,232,000 | 3,000,000 | 2,721,000 | 2,000,000 | 1,500,000 | 6,929,000 | 9,141,000 | 6,934,000 | 20,769,000 |
| total current assets | 215,504,000 | 163,844,000 | 107,946,000 | 56,937,000 | 65,526,000 | 36,981,000 | 27,441,000 | 25,712,000 | 22,755,000 | 6,941,000 | 17,590,000 | 18,776,000 | 18,232,000 | 32,199,000 |
| total assets | 460,180,000 | 237,229,000 | 183,928,000 | 122,928,000 | 112,400,000 | 65,402,000 | 56,942,000 | 51,851,000 | 33,805,000 | 13,644,000 | 24,423,000 | 26,095,000 | 25,645,000 | 43,949,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 13,604,000 | 5,260,000 | 7,777,000 | 7,311,000 | 11,422,000 | 3,682,000 | 1,576,000 | 3,588,000 | 2,787,000 | 1,218,000 | 881,000 | 1,200,000 | 1,277,000 | 1,965,000 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 3,295,000 | 853,000 | 4,475,000 | 482,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 42,764,000 | 27,194,000 | 40,203,000 | 21,148,000 | 17,084,000 | 18,080,000 | 7,740,000 | 9,581,000 | 6,444,000 | 2,996,000 | 3,389,000 | 2,067,000 | 7,941,000 | 11,343,000 |
| total current liabilities | 59,663,000 | 33,307,000 | 52,455,000 | 28,941,000 | 28,506,000 | 21,762,000 | 9,316,000 | 13,169,000 | 9,231,000 | 4,214,000 | 4,270,000 | 3,267,000 | 9,218,000 | 13,308,000 |
| loans | 221,972,000 | 16,976,000 | 18,740,000 | 15,814,000 | 82,306,000 | 73,728,000 | 68,778,000 | 54,510,000 | 2,000,000 | 0 | 0 | 0 | 123,000 | 0 |
| hp & lease commitments | 71,206,000 | 8,488,000 | 9,370,000 | 7,907,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 1,069,000 | 1,760,000 | 2,515,000 | 3,310,000 | 5,033,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,201,000 | 9,024,000 |
| other liabilities | 38,258,000 | 92,000 | 1,003,000 | 1,695,000 | 1,401,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 102,000 |
| provisions | 28,024,000 | 12,488,000 | 11,678,000 | 10,890,000 | 3,132,000 | 1,260,000 | 1,244,000 | 1,066,000 | 1,070,000 | 1,064,000 | 1,020,000 | 1,002,000 | 996,000 | 1,078,000 |
| total long term liabilities | 164,325,000 | 16,584,000 | 18,727,000 | 18,357,000 | 49,153,000 | 37,494,000 | 35,011,000 | 27,788,000 | 1,535,000 | 532,000 | 510,000 | 501,000 | 4,822,000 | 9,665,000 |
| total liabilities | 223,988,000 | 49,891,000 | 71,182,000 | 47,298,000 | 77,659,000 | 59,256,000 | 44,327,000 | 40,957,000 | 10,766,000 | 4,746,000 | 4,780,000 | 3,768,000 | 14,040,000 | 22,973,000 |
| net assets | 204,653,000 | 187,338,000 | 112,746,000 | 75,630,000 | 34,741,000 | 6,146,000 | 12,615,000 | 10,894,000 | 23,039,000 | 8,898,000 | 19,643,000 | 22,327,000 | 11,605,000 | 20,976,000 |
| total shareholders funds | 204,653,000 | 187,338,000 | 112,746,000 | 75,630,000 | 34,741,000 | 6,146,000 | 12,615,000 | 10,894,000 | 23,039,000 | 8,898,000 | 19,643,000 | 22,327,000 | 11,605,000 | 20,976,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | -30,220,000 | 20,768,000 | -5,694,000 | -14,467,000 | 13,915,000 | -5,668,000 | -11,313,000 | -14,083,000 | -10,613,000 | -12,823,000 | -10,487,000 | -14,438,000 | -12,011,000 | -5,730,000 |
| Depreciation | 20,271,000 | 12,435,000 | 9,598,000 | 5,765,000 | 4,332,000 | 4,113,000 | 1,264,000 | 703,000 | 671,000 | 601,000 | 336,000 | 345,000 | 311,000 | |
| Amortisation | 6,088,000 | 21,000 | 22,000 | 22,000 | 25,000 | 1,233,000 | 363,000 | 396,000 | 396,000 | 370,000 | 3,586,000 | 699,000 | 0 | |
| Tax | 817,000 | -869,000 | 327,000 | 4,823,000 | 2,527,000 | 2,744,000 | 3,666,000 | 3,963,000 | 2,137,000 | 1,667,000 | 1,619,000 | 1,671,000 | 1,514,000 | 1,579,000 |
| Stock | 3,104,000 | 2,609,000 | 4,333,000 | -1,672,000 | 919,000 | 1,130,000 | -504,000 | 1,299,000 | 727,000 | 680,000 | 0 | 0 | 0 | 0 |
| Debtors | 18,229,000 | -9,179,000 | 23,522,000 | 7,424,000 | 9,497,000 | 10,184,000 | -4,026,000 | 5,777,000 | 2,561,000 | 887,000 | -1,095,000 | -1,995,000 | 167,000 | 4,628,000 |
| Creditors | 8,344,000 | -2,517,000 | 466,000 | -4,111,000 | 7,740,000 | 2,106,000 | -2,012,000 | 801,000 | 1,569,000 | 337,000 | -319,000 | -77,000 | -688,000 | 1,965,000 |
| Accruals and Deferred Income | 14,879,000 | -13,764,000 | 18,260,000 | 2,341,000 | 4,037,000 | 10,340,000 | -1,841,000 | 3,137,000 | 3,448,000 | -393,000 | 1,322,000 | -10,075,000 | -8,225,000 | 20,367,000 |
| Deferred Taxes & Provisions | 15,536,000 | 810,000 | 788,000 | 7,758,000 | 1,872,000 | 16,000 | 178,000 | -4,000 | 6,000 | 44,000 | 18,000 | 6,000 | -82,000 | 1,078,000 |
| Cash flow from operations | 14,382,000 | 23,454,000 | -4,088,000 | -3,621,000 | 24,032,000 | 3,570,000 | -11,635,000 | -5,642,000 | -11,668,000 | -5,781,000 | -16,996,000 | -18,615,000 | 14,942,000 | |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | -10,966,000 | 8,012,000 | 2,297,000 | 657,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 204,996,000 | -1,764,000 | 2,926,000 | -66,492,000 | 8,578,000 | 4,950,000 | 14,268,000 | 52,510,000 | 2,000,000 | 0 | 0 | -123,000 | 123,000 | 0 |
| Hire Purchase and Lease Commitments | 65,160,000 | -4,504,000 | 5,456,000 | 8,389,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 38,166,000 | -911,000 | -692,000 | 294,000 | 1,401,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -102,000 | 102,000 |
| share issue | ||||||||||||||
| interest | -15,756,000 | -888,000 | -878,000 | -6,422,000 | -8,901,000 | -3,261,000 | -4,890,000 | -1,865,000 | -182,000 | 60,000 | 138,000 | 136,000 | 207,000 | 636,000 |
| cash flow from financing | 349,038,000 | 47,514,000 | 50,173,000 | -7,276,000 | 22,132,000 | 4,237,000 | 27,740,000 | 51,519,000 | 24,620,000 | 411,000 | 6,184,000 | 23,366,000 | 1,151,000 | 25,229,000 |
| cash and cash equivalents | ||||||||||||||
| cash | 32,341,000 | 62,201,000 | 30,500,000 | -16,001,000 | 17,915,000 | -1,006,000 | 5,980,000 | -4,840,000 | 12,026,000 | -6,787,000 | 2,121,000 | 182,000 | -149,000 | 6,802,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 32,341,000 | 62,201,000 | 30,500,000 | -16,001,000 | 17,915,000 | -1,006,000 | 5,980,000 | -4,840,000 | 12,026,000 | -6,787,000 | 2,121,000 | 182,000 | -149,000 | 6,802,000 |
oxford biomedica plc Credit Report and Business Information
Oxford Biomedica Plc Competitor Analysis
Perform a competitor analysis for oxford biomedica plc by selecting its closest rivals and benchmarking them against 12 key performance metrics.
oxford biomedica plc Ownership
OXFORD BIOMEDICA PLC group structure
Oxford Biomedica Plc has 3 subsidiary companies.
Ultimate parent company
OXFORD BIOMEDICA PLC
03252665
3 subsidiaries
oxford biomedica plc directors
Oxford Biomedica Plc currently has 14 directors. The longest serving directors include Mr Stuart Henderson (Jun 2016) and Mr Stuart Paynter (Aug 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Stuart Henderson | 65 years | Jun 2016 | - | Director | |
| Mr Stuart Paynter | 52 years | Aug 2017 | - | Director | |
| Mr Stuart Paynter | 50 years | Aug 2017 | - | Director | |
| Dr Heather Preston | United States | 58 years | Mar 2018 | - | Director |
| Mr Robert Ghenchev | 41 years | Jun 2019 | - | Director | |
| Mr Frederic Doliveux | 67 years | Jun 2020 | - | Director | |
| Ms Kay Davies | England | 73 years | Mar 2021 | - | Director |
| Dr Michael Hayden | 72 years | Jul 2021 | - | Director | |
| Ms Catherine Moukheibir | England | 64 years | Dec 2021 | - | Director |
| Ms Catherine Moukheibir | England | 64 years | Dec 2021 | - | Director |
P&L
December 2022turnover
140m
-2%
operating profit
-30.2m
-246%
gross margin
49.5%
-14.61%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
204.7m
+0.09%
total assets
460.2m
+0.94%
cash
141.3m
+0.3%
net assets
Total assets minus all liabilities
oxford biomedica plc company details
company number
03252665
Type
Public limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
September 1996
age
28
accounts
Group
ultimate parent company
previous names
pinco 838 limited (October 1996)
incorporated
UK
address
windrush court transport way, oxford, OX4 6LT
last accounts submitted
December 2022
oxford biomedica plc Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 5 charges/mortgages relating to oxford biomedica plc. Currently there are 2 open charges and 3 have been satisfied in the past.
oxford biomedica plc Companies House Filings - See Documents
| date | description | view/download |
|---|
